About us

Concepts for Innovative Cancer Drug Development           

Create New Horizons

 

Hentsch Consulting provides advisory support for innovative drug development programs focussing on oncology.

Our first activities for selected clients in the life science industry were initiated in 2008. Starting in 2014, we now also provide our services to a broader range of customers.

Our business is managed by Dr. Bernd Hentsch who is looking back on a professional track record of more than two decades in both, international academic research, as well as in drug development in various pharmaceutical and biotech companies. His background comprises a PhD in molecular biology with a focus on oncology and immunology, academic research positions in Germany and Australia, as well as in preclinical and clinical cancer and inflammatory drug development in the international pharmaceutical and biotech industry.

Dr. Bernd Hentsch has been a biotech founder and entrepreneur over many years and has held executive positions (CEO, CDO) in private and also publicly listed companies. Please find below a short summary of his professional cornerstones and a list of relevant publications.

Professional cornerstones

 

May 2020

Scientific update 2018 - 2020

During the past 2 years I supported the development of INTH-454, a new small molecule acting with a new mode-of-action. Data were presented on posters on the following oncology conferences: ASCO 2019, AACR-EORTC 2019 and ASCO 2018

 

March 2018

Besides my consultancy activities, I have now also taken up the role as Chief Development Officer of the young Swiss start-up biotech company Inthera Bioscience AG, located near Zürich.

 

Since 2014

Hentsch Consulting

Cancer Drug Development

Founder

 

2008 - 2014

4SC AG, Martinsried, Germany

Chief Development Officer (CDO)

 

2005 - 2008

TopoTarget A/S, Copenhagen, Denmark

Chief Development Officer (CDO)

&

TopoTarget Germany AG (formerly G2M Cancer Drugs AG)

Frankfurt am Main, Germany

Executive Board Member (Vorstand)

 

2005

Trade sale of G2M Cancer Drugs AG (re-named to TopoTarget Germany AG) to

TopoTarget A/S, Copenhagen, Denmark (Feb 2005)

IPO of TopoTarget A/S (June 2005)

 

2001 - 2005

G2M Cancer Drugs AG, Frankfurt am Main, Germany

Co-Founder and first Chief Executive Officer (CEO)

 

1997 - 2001

Merck KGaA, Darmstadt, Germany

Deputy Head of the Department of Preclinical Oncology

Speaker of the Genomics Research Program in Oncology

 

1995 - 1996

DKFZ, Deutsches Krebsforschungszentrum (German Cancer Research Center)

Heidelberg, Germany

Research Scientist / Junior Group Leader

 

1993 - 1995

Walter & Eliza Hall Institute of Medical Research

Melbourne, Australia

Post-Doc with Research Fellowship of Deutsche Forschungsgemeinschaft, DFG (German Society of Research)

 

1989 - 1992

University of Würzburg, Institute of Virology and Immunobiology

Würzburg, Germany

PhD thesis

 

List of Publications (B. Hentsch)

 

Peer Reviewed Journal Articles

 

Bitzer M, Horger M, Giannini EG, Ganten TM, Wörns MA, Siveke JT, Dollinger MM, Gerken G, Scheulen ME, Wege H, Zagonel V, Cillo U, Trevisani F, Santoro A, Montesarchio V, Malek NP, Holzapfel J, Herz T, Ammendola AS, Pegoraro S, Hauns B, Mais A, Lauer UM, Henning SW, Hentsch B (2016): Resminostat in combination with sorafenib as second-line therapy of advanced hepatocellular carcinoma - The SHELTER Study. J Hepatol. 2016 Aug;65(2):280-8.

 

Brunetto AT, Ang JE, Lal R, Olmos D, Molife LR, Kristeleit R, Parker A, Casamayor I, Olaleye M, Mais A, Hauns B, Strobel V, Hentsch B, de Bono JS (2013): First-in-human, pharmacokinetic and pharmacodynamic phase I study of Resminostat, an oral histone deacetylase inhibitor, in patients with advanced solid tumors. Clin Cancer Res. 2013 Oct 1;19(19):5494-504.

 

Herrlinger KR, Diculescu M, Fellermann K, Hartmann H, Howaldt S, Nikolov R, Petrov A, Reindl W, Otte J.M, Stoynov S, Strauch U, Sturm A, Voiosu R, Ammendola A, Dietrich B, Hentsch B, Stange EF (2011):  Efficacy, Safety and Tolerability of Vidofludimus in Patients with Inflammatory Bowel Disease: the ENTRANCE Study. J Crohns Colitis. 2012 Oct 15. 

 

Atmaca A, Al-Batran SE, Maurer A, Neumann A, Heinzel T, Hentsch B, Schwarz SE, Hövelmann S, Göttlicher M, Knuth A, Jäger E (2007): Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial. Br J Cancer. 2007 Jul 16;97(2):177-82. 

 

Zubakov D, Hoheisel JD, Kluxen FW, Brändle M, Ehring T, Hentsch B, Frohme M (2003): Late ischemic preconditioning of the myocardium alters the expression of genes involved in inflammatory response. FEBS Lett. 2003 Jul 17;547(1-3):51-5.

 

Zolk O, Frohme M, Maurer A, Kluxen FW, Hentsch B, Zubakov D, Hoheisel JD, Zucker IH, Pepe S, Eschenhagen T (2002): Cardiac ankyrin repeat protein, a negative regulator of cardiac gene expression, is augmented in human heart failure. Biochem Biophys Res Commun. 2002 May 24;293(5):1377-82.

 

Hentsch B, Lyons I, Li R, Hartley L, Lints TJ, Adams JM, Harvey RP (1996): Hlx homeo box gene is essential for an inductive tissue interaction that drives expansion of embryonic liver and gut. Genes Dev. 1996 Jan 1;10(1):70-9.

 

Pfeuffer I, Klein-Hessling S, Heinfling A, Chuvpilo S, Escher C, Brabletz T, Hentsch B, Schwarzenbach H, Matthias P, Serfling E(1994): Octamer factors exert a dual effect on the IL-2 and IL-4 promoters. J Immunol. 1994 Dec 15;153(12):5572-85.

 

Hentsch B, Mouzaki A, Pfeuffer I, Rungger D, Serfling E The weak, fine-tuned binding of ubiquitous transcription factors to the Il-2 enhancer contributes to its T cell-restricted activity. Nucleic Acids Res. 1992 Jun 11;20(11):2657-65.

 

Briegel K*, Hentsch B*, Pfeuffer I, Serfling E. (1991): One base pair change abolishes the T cell-restricted activity of a kB-like proto-enhancer element from the interleukin 2 promoter (*equal contribution). Nucleic Acids Res. 1991 Nov 11;19(21):5929-36.

 

Conference Presentations

 

Abstract and Poster Conference Presentations

 

Oncology drug development

 

INTH-454 – epigenetic modulator of p300/CBP as a new anti-cancer drug candidate

Valentino Cattori, Bernd Hentsch, Ulrich Kessler (2019): Targeting the p300/CBP interactome through blockage of the CH1-domain triggers tumor regression in AR-positive and AR-negative xenograft models of castration-resistant prostate cancer (CRPC). DOI: 10.1200/JCO.2019.37.15_suppl.3105 Journal of Clinical Oncology 37, no. 15_suppl (May 20, 2019) 3105-3105 (Poster ASCO 2019).

 

Valentino Cattori, Bernd Hentsch and Ulrich Kessler (2019): INTH-454, a p300/CBP interactome modulator, targets multiple pathogenesis factors in solid tumors and induces strong anti-proliferative effects in vitro and in vivo as single agent. Mol Cancer Ther 2019;18(12 Suppl): Abstract nr C040. doi: 10.1158/1535-7163.TARG-19-C040 (Poster AACR EORTC 2019).

 

Ulrich Kessler, Valentino Cattori, Marc Labelle, Bernd Hentsch (2018): Oral small molecule modulators of p300/CBP to reprogram cancer cells and reactivate the p53 pathway in HPV-associated carcinomas. DOI: 10.1200/JCO.2018.36.15_suppl.e14581 Journal of Clinical Oncology 36, no. 15_suppl (Poster ASCO 2018).

 

Resminostat (4SC-201) – an epigenetic new cancer drug (HDAC inhibitor)

 

Bernhard Hauns , Henning Schulze-Bergkamen , Dirk Jaeger , Hans-Georg Kopp , Michael Bitzer, Babett Krauss, Stefan W. Henning , Bernd Hentsch , Wilhelm Haverkamp (2014): Centralized analysis of phase II ECG dataset of resminostat, an orally available histone-deacetylase inhibitor (HDACi). DOI: 10.1200/jco.2014.32.15_suppl.e13526 Journal of Clinical Oncology 32, no. 15_suppl Published online May 20, 2014 (Abstract ASCO annual meeting 2014).

 

Baumgartner R, Henning SW, Hauns B, Ammendola A, Krauss B, Holzapfel J, Bitzer M, Hentsch B (2014): Population PK/PD analysis of the pan-HDAC inhibitor resminostat. DOI: 10.1200/jco.2014.32.15_suppl.e13527 Journal of Clinical Oncology 32, no. 15_suppl (Abstract ASCO annual meeting 2014).

 

Bitzer M, Mais A, Hauns B, Asche J, Herz T, Pegoraro S, Ammendola A, Henning SW, Hentsch B, SHELTER Study Group (2013): Subgroup analysis of prognostic factors for overall survival in the SHLTER trial evaluating resminostat in advanced hepatocellular carcinoma (HCC). European Cancer Congress (ECCO), Abstract Book 2.601; Poster Board P429, Poster Session on “Gastrointestinal Malignancies, Noncolorectal”. 27 Sep - 1 Oct 2013, Amsterdam.

 

Schulze-Bergkamen H, Jäger D, Kopp H-G, Bitzer M, Mais A, Resemann K, Hauns B, Asche J, Henning SW, Hentsch B, SHORE Study Group (2013): Phase I dose escalation of the oral histone deacetylase inhibitor (HDACi) resminostat in combination with FOLFIRI in colorectal cancer (CRC) patients: the SHORE trial. Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago (USA) 31 May - 4 June, 2013.

 

Hauns B, Mais A, Doblhofer R, Henning SW, Hentsch B, Bitzer B, SHELTER Study Group (2013): Pharmacokinetic characteristics of the new treatment combination of sorafenib and resminostat, a novel histone deacetylase (HDAC) inhibitor, in patients with advanced hepatocellular carcinoma (HCC): the SHELTER study. 3rd ITLT Essen 2013: Interdisciplinary Treatment of Liver Tumors Essen/Germany, 18 - 20 April, 2013. Digestive and Liver Disease 45(Supplement 3(0)):S251 · April 2013, DOI: 10.1016/S1590-8658(13)60673-8.

 

Michael Bitzer, Tom M. Ganten, Marcus A. Woerns, Jens T. Siveke, Matthias M. Dollinger, Max E. Scheulen, Henning Wege, Edoardo G. Giannini, Umberto Cillo, Franco Trevisani, Armando Santoro, Vincenzo Montesarchio, Anna Mais, Bernhard Hauns, Julia Asche, Thomas Herz, Stefano Pegoraro, Aldo Ammendola, Stefan W. Henning, Bernd Hentsch (2013): Resminostat in advanced hepatocellular carcinoma (HCC): Overall survival subgroup analysis of prognostic factors in the SHELTER trial. DOI: 10.1200/jco.2013.31.15_suppl.e15088 Journal of Clinical Oncology 31, no. 15_suppl Published online May 20, 2013. 

 

Mais A, Henning SW, Hauns B, Hentsch B (2009): Rationale for the combination of established oncological therapies with Resminostat, a novel Histone Deacetylase (HDAC) inhibitor. CESAR (Central European Society for Anticancer Drug Research) Annual Meeting 2012, CESAR Abstract book, poster 32, page 65 (CESAR Annual Meeting, 2012, Essen, Germany).

 

Bitzer B, Horger H, Ganten T, Siveke J, Woerns MA, Dollinger MM, Zagonel V, Cillo U, Gerken G, Scheulen ME, Wege H, Giannini E, Montesarchio V, Trevisani F, Mais A, Jankowsky R, Hauns B, Hentsch B, Lauer UM (2012): Investigation of the HDAC Inhibitor Resminostat in Patients with Sorafenib-Resistant Hepatocellular Carcinoma (HCC): Clinical Data from the Phase I/II SHELTER Study. J Clin Oncol 30, 2012 (suppl 4; abstr 262) (ASCO Gastrointestinal Cancers Symposium 2012, San Francisco). DOI: 10.1200/jco.2012.30.4_suppl.262.

 

Bauer S, Schulze-Bergkamen H, Jäger D, Mayer F, Bitzer M, Hauns B, Resemann K, Jankowsky R, Mais A, Kohlhof H, Hentsch B (2012): A Phase I/II Study of Resminostat, an Oral Histone Deacetylase Inhibitor (HDACi), in Combination with FOLFIRI as Second-Line Treatment in KRAS Mutated Colorectal Cancer (CRC) patients - the SHORE Study Ann Oncol (2012) 23(suppl 4):iv119-iv127 doi:10.1093/annonc/mds154 (ESMO 14th World Congress on GI Cancers 2012, Barcelona).

 

Ganten TM, Woerns MA, Siveke J, Dollinger MM, Scheulen ME, Wege H, Mais A, Hauns B, Henning SW, Hentsch B, Horger M, Lauer UM, Bitzer M (2012): Dose Escalation of the HDAC Inhibitor Resminostat in Combination Treatment with Sorafenib in Patients with Hepatocellular Carcinoma (HCC) - The Phase I/II SHELTER study. Ann Oncol (2012) 23(suppl 4): iv119-iv127(ESMO 14th World Congress on GI Cancers 2012, Barcelona). DOI: 10.1016/S0923-7534(20)30289-1.

 

Bitzer M, Horger M, Ganten T, Lauer UM, Woerns MA, Siveke J, Dollinger MM, Gerken G, Scheulen ME, Wege H, Giannini E, Zagonel V, Cillo U, Trevisani F, Santoro A, Montesarchio V, Mais A, Asche J, Jankowski R, Hauns B, Hentsch B (2012): Efficacy, safety, tolerability and PK of the HDAC inhibitor resminostat in sorafenib-refractory hepatocellular carcinoma (HCC): Phase II SHELTER study. J Clin Oncol 30, 2012 (suppl; abstr 4115) (ASCO Annual Meeting 2012, Chicago). DOI: 10.1200/jco.2012.30.15_suppl.4115 Journal of Clinical Oncology - published online before print May 20, 2012.

 

Walewski J, Borsaru G, Moicean A, Hellmann A, Janikova A, Hauns B, Mais A, Ammendola A, Herz T, Kohlhof H, Henning SW, Hentsch B (2012): Efficient HDAC inhibition and TARC reduction in patients with refractory Hodgkin’s lymphoma treated with Resminostat PK/PD data from the Phase II SAPHIRE study. Program book, no 206, p.107) Haematologica 2012;97:supplement (http://online.haematologica.org/meetings/) (17th Congress of the European Hematology Association, Amsterdam 2012). 

 

M Bitzer, M Horger, TM Ganten, J Siveke, MA Woerns, M Dollinger, G Gerken, ME Scheulen, H Wege, A Mais, R Jankowsky, B Hauns, B Hentsch, UM Lauer (2012): Combination Treatment of Sorafenib and Resminostat, a new HDAC Inhibitor, in Patients with Sorafenib-resistant Hepatocellular Carcinoma (HCC) – Results of the Dose-Escalation Phase. Zeitschrift für Gastroenterologie 2012; 50 - P5_06 DOI: 10.1055/s-0031-1295962.

 

Bitzer B, Horger M, Ganten T, Ebert MP, Siveke J, Woerns MA, Dollinger MM, Gerken G, Scheulen ME, Mais A, Jankowsky R, Hauns B, Hentsch B, Lauer UM (2011): Clinical Update of the SHELTER Study: A Phase I/II Trial of HDAC Inhibitor Resminostat in Patients with Sorafenib-Resistant Hepatocellular Carcinoma (HCC) Ann Oncol (2011) 22(suppl 5): v134-v144doi:10.1093/annonc/mdr288 (ESMO 13th World Congress on Gastrointestinal Cancer 2011, Barcelona).

 

Bitzer M, Horger M, Ganten T, Ebert MP, Woerns MA, Dollinger MM, Kirsch A, Gerken G, Scheulen ME, Jankowsky R, Mais A, Hauns B, Hentsch B, Lauer UM (2011): Clinical Update of the SHELTER Study: A Phase I/II Trial of HDAC Inhibitor Resminostat in Patients with Sorafenib-Resistant Hepatocellular Carcinoma (HCC). J Clin Oncol 29: 2011 (suppl 4; abstr 275) (ASCO Gastrointestinal Cancers Symposium 2011, San Francisco).

 

Hauns B, Mais A, Jankowsky R, Hentsch B, Haverkamp W (2010): Central ECG analysis of resminostat, a new oral histone deacetylase inhibitor (HDACi), in clinical development as anticancer compound. J Clin Oncol 28, 2010 (suppl; abstr e13609) (ASCO Annual Meeting 2010, Chicago).

Bitzer M, Horger M, Ganten TM, Ebert MP, Siveke JT, Woerns MA, Dollinger MM, Gerken G, Scheulen ME, Mais A, Jankowsky R, Hauns B, Hentsch B, Lauer UM (2011): Clinical update on a phase I/II trial of HDAC inhibitor resminostat in patients with sorafenib-resistant hepatocellular carcinoma (HCC): The SHELTER study. J Clin Oncol 29: 2011 (suppl; abstr e13603) (ASCO Annual Meeting 2011, Chicago). 

 

Hauns B, Mais A, Jankowsky R, Hentsch B, Haverkamp W (2010): Centralised Analysis of Phase I ECG Dataset of Resminostat, a New Oral Histone Deacetylase Inhibitor (HDACi) European Journal of Cancer, Volume 8, Number 7, November 2010 (22nd EORTC NCI AACR Symposium on Molecular Targets and Cancer Therapeutics 2010, Berlin).

 

Bitzer, M, Horger, M, Ebert, M, Ganten, T, Wörns, M, Dollinger, M, Hauns, B, Mais, A, Jankowsky, R, Hentsch B, Lauer, UM (2010): First clinical data of resminostat, a novel oral histone deacetylase (HDAC) inhibitor, in patients with hepatocellular carcinoma (HCC) - the SHELTER study. (Jahrestagung DGVS Viszeralmedizin 2010, Stuttgart, Germany) Zeitschrift für Gastroenterologie 2010; 48 -P432.http://www.viszeralmedizin.com/10_0816_Hauptprogramm_download_dgvs_doppelseiten.pdf)

 

Bitzer M, Horger M, Ebert MP, Ganten T, Woerns MA, Hauns B, Mais A, Jankowsky R, Hentsch B and Lauer UM (2010): First clinical data of resminostat, a novel oral histone deacetylase (HDAC) inhibitor, in patients with hepatocellular carcinoma (HCC): The SHELTER study.  J Clin Oncol 28, 2010 (suppl; abstr e14661) (ASCO Annual Meeting 2010, Chicago).

 

Walewski J, Paszkiewicz-Kozik E, Borsaru G, Moicean A, Warszewska A, Strobel K, Biggi A, Hauns B, Mais A, Henning SW, Hentsch B (2010): Resminostat in Relapsed or Refractory Hodgkin Lymphoma: Initial Results of the SAPHIRE Phase II Trial with a Novel Oral Histone Deacetylase (HDAC) inhibitor Blood (ASH Annual Meeting Abstracts) 2010; vol. 116, nr 21, Abstract 2811,Poster Board # II-691 (52nd ASH Annual Meeting 2010, Orlando).

 

Walewski J, Paszkiewicz-Kozik E, Warszewska A, Borsaru G, Moicean A, Hellmann A, Mayer J, Hauns B, Mais A, Henning SW and Hentsch B (2011): Final Results of the Phase II SAPHIRE Trial of Resminostat (4SC-201) in Patients with Relapsed/Refractory Hodgkin Lymphoma. Blood 2011; vol. 118, nr 21, p. 245, Abstract no 2675 (53rd ASH Annual Meeting 2011, San Diego).

 

Kohlhof H, Jankowsky R, Hentsch B (2009): The oral histone deacetylase (HDAC) inhibitor 4SC-201: in vitro and in vivo data. Keystone Symposia on Molecular and cellular biology 2009. Deregulation of transcription in cancer: Controlling cell fate decisions. Abstract no 224, abstract book p.68 (Keystone Symposia June 21-26, 2009, Ireland).

 

Jankowsky R, Mais A, Henning SW, Hauns B, Hentsch B (2010): Clinical Phase II Development of Resminostat, a Novel HDAC Inhibitor. 22nd EORTC-NCI-AACR symposium on “Molecular Targets and Cancer Therapeutics”, 16-19 November 2010, Abstract # 540, p172. European Journal of Cancer, Volume 8, Number 7, November 2010 (22nd EORTC-NCI-AACR symposium 2010, Berlin)

 

de Bono JS, Brunetto AT, Kristeleit R, Doblhofer R, Jankowsky R, Mais A, Hauns B, Hentsch B (2009): Clinical and preclinical development of 4SC-201, a new oral histone deacetylase (HDAC) inhibitor. European Journal of Cancer, Vol. 7, No. 2, September 2009 (ECCO 15 ESMO 34 Conference 2009, Berlin).

 

Other small molecule oncology medical product candidates

 

Domatinostat (4SC-202) – an epigenetic HDAC inhibitor

 

Bastian von Tresckow, Stefan Gundermann, Dennis A. Eichenauer, Walter Erich Aulitzky, Mariele Göbeler, Cyrus Sayehli, Liza Bacchus, Bernhard Hauns, Anna Mais, Bernd Hentsch, Hella Kohlhof, Rolf Krauss, Babett Krauss, Roland Baumgartner, Daniel Vitt, Andreas Engert (2014): First-in-human study of 4SC-202, a novel oral HDAC inhibitor in advanced hematologic malignancies (TOPAS study). J Clin Oncol 32:5s, 2014 (suppl; abstr 8559) (ASCO Annual Meeting 2014, Chicago). 

 

Henning SW, Doblhofer R, Kohlhof H, Jankowsky R, Maier T, Beckers T, Schmidt M and Hentsch B (2010): Preclinical characterization of 4SC-202, a noval isotype specific HDAC inhibitor. European Journal of Cancer, Volume 8, Number 7, November 2010, abstract 178, p.61, poster Board no.135 (22nd EORTC-NCI-AACR symposium on “Molecular Targets and Cancer Therapeutics” 2010, Berlin).

 

Inhibitor of the Eg5 kinesin spindle protein

 

Klaus B. Mross, Dirk Scharr, Heike Richly, Annette Frost, Sebastian Bauer, Babett Krauss, Rolf Krauss, Anna Mais, Bernhard Hauns, Bernd Hentsch, Roland Baumgartner, Max E. Scheulen (2014): First-in-human study of 4SC-205 (AEGIS), a novel oral inhibitor of Eg5 kinesin spindle protein. J Clin Oncol 32:5s, 2014 (suppl; abstr 2564) (ASCO Annual Meeting 2014, Chicago).  

 

A novel multi-kinase inhibitor

 

Krauss R, Wagner F, Doblhofer R, Dietrich D, Ehlert J, Kubbutat MHG, Lingnau A, Totzke F, Schächtele C, Hentsch B (2011):Preclinical and Clinical Development of 4SC-203, a Novel Multi-Target Kinase Inhibitor. European Journal of Cancer, Volume 47, Supplement 1, September 2011 (ESMO 36 ECCO 16 ESTRO 30, The European Multidisciplinary Cancer Congress 2011, Stockholm).

 

A novel anti-mitotic cancer drug candidate

 

Ammendola A, Krauss R, Doblhofer R, Strobl S, Hamm S, Schmidt M, Gimmnich P, Pekari K, Zimmermann A, Hentsch B (2010): 4SC-207, a novel and highly potent anti-mitotic agent, active also on PgP expressing tumor cells resistant to other chemotherapeutic drugs, induces complete tumor stasis in in vivo tumor models. European Journal of Cancer, Volume 8, Number 7, November 2010 (22nd EORTC-NCI-AACR symposium on “Molecular Targets and Cancer Therapeutics” 2010, Berlin).

 

Baumgartner R, Krauss R, Hamm S, Doblhofer R, Hentsch B (2011): The effect of 4SC-207, a novel antimitotic agent, on multidrug-resistant cell lines. J Clin Oncol 29: 2011 (suppl; abstr e14090 (ASCO Annual Meeting 2011, Chicago). DOI: 10.1200/jco.2011.29.15_suppl.e14090.

Inflammatory diseases drug development

 

Vidofludimus – an immune-modulating medicinal product candidate

 

Hamm S, Henning SW, Hentsch B, Vitt D, Groeppel M, Ammendola A (2012): Vidofludimus induces p53-mediated apoptosis in activated T cells and inhibits IL-17A and IL-17F expression decoupled from lymphocyte proliferation. Gastroenterology 2012;142(5), Supp 1, S-867 (Digestive Disease Week 2012, Chicago).

 

Sierakowski S, Dietrich B, Hentsch B, Ammendola A (2011): Efficacy, Safety and Pharmacokinetics of Vidofludimus, a Novel Oral Immunomodulator, in Patients with Active Rheumatoid Arthritis on Methothrexate Background Therapy: The COMPONENT study. Arthritis Rheum 2011; 63 Suppl 10:397 (Annual Meeting of the American College of Rheumatology  2011, Chicago).

 

Hamm S, Henning SW, Hentsch B, Vitt D, Groeppel M, Ammendola A (2012): Vidofludimus induces p53-mediated apoptosis in activated T cells and inhibits IL-17A and IL-17F expression decoupled from lymphocyte proliferation. J Crohns Colitis 2012; 6(1):S16 (7th Congress of ECCO 2012, Barcelona).

 

Kulkarni O, Anders H-J, Doblhofer R, Hentsch B, Ammendola A (2011): Vidofludimus shows a superior profile compared to cyclophosphamide and MMF in an experimental systemic lupus erythematosus model. Ann Rheum Dis 2011; 70(Suppl3):677 (Annual European Congress of Rheumatology 2011, London).

 

Herrlinger KR, Diculescu M, Fellermann K, Hartmann H, Howaldt S, Nikolov R, Petrov A, Reindl W, Otte JM, Stoynov S, Strauch U, Sturm A, Voiosu R, Ammendola A, Dietrich B, Hentsch B, Stange EF (2011): Efficacy, Safety and Tolerability of Vidofludimus in Patients with Inflammatory Bowel Disease: the ENTRANCE Study. Gastroenterology 2011;140(5), Supp 1, S-588-9 (Digestive Disease Week 2011, Chicago).

 

Herrlinger KR, Diculescu M, Fellermann K, Hartmann H, Howaldt S, Nikolov R, Petrov A, Reindl W, Otte JM, Stoynov S, Strauch U, Sturm A, Voiosu R, Ammendola A, Dietrich B, Hentsch B, Stange EF (2011): Efficacy, Safety and Tolerability of Vidofludimus in Patients with Inflammatory Bowel Disease: the ENTRANCE Study. J Crohns Colitis 2011; 5(1):S100-101 (6th Congress of ECCO, Dublin 2011).

 

Oral Conference Presentations (Speaker: B. Hentsch)

 

Resminostat: A novel HDAC inhibitor in development for the treatment of advanced hepatocellular carcinoma - a biomerker driven approach.

CHI 21st International Molecular Med TRI-CON 2014

Session: Clinical Epigenetics

San Francisco, 9-14 February 2014

 

Resminostat: A Novel Oral Histone Deacetylase Inhibitor in Phase II Clinical Development.

2nd World Epigenetics Summit

Munich, 7-8 of December 2011

 

Resminostat: A Novel Oral Histone Deacetylase Inhibitor in Phase II Clinical Development World Epigenetics Summit

Boston, 27-28 July 2011

 

The new Oncology Compounds 4SC-201, resminostat (HDAC Inhibition), and 4SC-203 (Kinase-Inhibition) as Examples for Clinical Development using Biomarker Analysis.

Healthcare of Tomorrow, Personalized Medicine Made in Bavaria

Session IV – Clinical Development

Munich, 27 April 2010

 

Other type of publication

 

Written commentary article: ”Exploiting epigenetics”

Authors: Hentsch B, Vitt D

MedNous, Opportunities in European Medical Innovation Vol 6, No 9 October 2012